Drugs / Peptides from HPV-16 E6 and E7
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02065973 Comparator | Feb 2014 → Dec 2015 | — | PDS Biotechnology Corp. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peptides from HPV-16 E6 and E7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02065973 ↗ |
| Modality | Peptide | “Peptides from HPV-16 E6 and E7” NCT02065973 ↗ |
| Route | Subcutaneous | “All subjects will receive 3 vaccinations SC given approximately 21 days apart.” NCT02065973 ↗ |